SCROLL TO CONTACT A REP

PRALUENT^® (alirocumab) Dosing

In patients with clinical ASCVD or HeFH, on top of maximally tolerated statins,

PRALUENT is the only PCSK9i with 2 powerful levels of efficacy to allow you to adjust the dose based on each patient’s LDL-C lowering needs¹

The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage
Measure LDL-C levels within 4 to 8 weeks of initiating PRALUENT 75 mg Q2W or just prior to the next scheduled dose for patients receiving PRALUENT 300 mg Q4W
If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks. For patients adjusting from 300 mg Q4W, start the new dose on the next scheduled dosing date

^*The 300-mg monthly dose of PRALUENT is administered as 2 consecutive, subcutaneous 150-mg injections at 2 different injection sites every 4 weeks.¹

Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo
The once-monthly (Q4W) 300 mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms

PRESCRIBE PRALUENT:
LDL-C lowering power with flexible dosing options¹

Reference:

PRALUENT^® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.